Rapport Therapeutics (RAPP) COO Cheryl Gault Sells Shares

What Happened Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, reported two open-market sales on September 30, 2026, disposing of a total of 10,000 shares for aggregate proceeds of about $331,856. The filings show 7,925 shares sold at a reported weighted-average price of $33.04 (proceeds ~$261,813) and 2,075 shares sold at a reported weighted-average price of $33.76 (proceeds ~$70,043). These were sales (not purchases) and were effected under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-09-30; Form 4 filed 2026-10-01 (timely filing).
• Sales:
  • 7,925 shares @ reported weighted avg $33.04 = $261,813 (footnote: actual sale prices ranged $32.64–$33.62).
  • 2,075 shares @ reported weighted avg $33.76 = $70,043 (footnote: actual sale prices ranged $33.64–$34.00).
• Total shares sold: 10,000; total proceeds ≈ $331,856.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Footnotes: F1—transactions executed pursuant to a 10b5-1 plan adopted Dec 10, 2025. F2/F3—reported prices are weighted averages; the filer can provide per-price breakdowns on request.

Context Sales made under Rule 10b5-1 plans are pre-scheduled and commonly viewed as routine liquidity events rather than direct indicators of insider sentiment. This report documents sales only; there were no option exercises, grants, or gifts reported in this filing.